Clinical Data BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial Pharmaceutical TechnologyAn indirect comparison highlights the potential of BridgeBio's Attruby to best Pfizer's tafamidis in frontline ATTR-CM.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology An indirect comparison highlights the potential of BridgeBio’s Attruby to best Pfizer’s tafamidis in frontline ATTR-CM. Cardiovascular Read full story Post navigation Previous: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)Next: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026